R&D | December 31, 2025
Sinopia Biosciences scores NIH grant to supercharge AI-driven drug discovery
The funding will accelerate Sinopia’s data-driven drug discovery efforts
The funding will accelerate Sinopia’s data-driven drug discovery efforts
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The plant is expected to enhance regional supply capabilities
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
Harbour BioMed brings advanced antibody discovery platforms to the table
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections
Subscribe To Our Newsletter & Stay Updated
